Business Context and Reporting Period
Company: The Estée Lauder Companies Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: A global leader in prestige beauty, manufacturing and marketing skin care, makeup, fragrance, and hair care products. The company operates approximately 1,600 freestanding stores and sells products in approximately 150 countries under brands including Estée Lauder, Clinique, M·A·C, La Mer, TOM FORD, and Dr.Jart+.
Key Financial Metrics
| Metric (in millions) | Fiscal 2024 | Fiscal 2023 | Change |
|---|---|---|---|
| Net Sales | $15,608 | $15,910 | (2)% |
| Gross Profit | $11,184 | $11,346 | (1)% |
| Gross Margin | 71.7% | 71.3% | +40 bps |
| Operating Income | $970 | $1,509 | (36)% |
| Operating Margin | 6.2% | 9.5% | -330 bps |
| Net Earnings (Attributable to Company) | $390 | $1,006 | (61)% |
| Diluted EPS | $1.08 | $2.79 | (61)% |
| Cash and Cash Equivalents | $3,395 | $4,029 | (16)% |
| Total Debt | $7,771 | $8,114 | (4)% |
| Operating Cash Flow | $2,360 | $1,731 | +36% |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 2% (1% in constant currency) driven by volume declines of 8%, partially offset by pricing increases of 7%. The decline was primarily due to softness in mainland China and Asia travel retail.
- Product Category Performance:
- Skin Care: Sales declined 4% due to lower sales from Estée Lauder, Clinique, and Dr.Jart+, partially offset by growth in La Mer and The Ordinary.
- Makeup: Sales decreased 1%, impacted by M·A·C (unfavorable year-over-year impact from deferred revenue recognition in 2023) and TOM FORD.
- Fragrance: Sales increased 1%, driven by Le Labo and Jo Malone London.
- Geographic Performance:
- Asia/Pacific: Sales decreased 6% due to mainland China softness and lower demand in Korea (Dr.Jart+).
- Europe, Middle East & Africa: Sales decreased 1%, primarily reflecting lower Asia travel retail sales.
- The Americas: Sales increased 1%, driven by growth in Mexico, Brazil, and the U.S. (TOM FORD royalty revenue).
- Impairment Charges: The company recorded a total of $471 million in impairment charges ($291 million goodwill and $180 million trademark) related to the Dr.Jart+ reporting unit due to lower-than-expected growth and a strategic shift to exit the travel retail channel.
- Restructuring: Launched the "Profit Recovery and Growth Plan" (PRGP) with a two-year restructuring program expected to cost $500–$700 million, targeting a net reduction of 1,800–3,000 positions.
Guidance, Outlook, and Risks
- Outlook: Management expects continued volatility, particularly in Asia travel retail and mainland China due to consumer sentiment. Competitive pressures and a slowdown in prestige beauty growth are anticipated in North America. Further business disruption is expected in Israel and the Middle East.
- Tax Rate: The effective tax rate for fiscal 2024 was 47.0%, significantly higher than the prior year's 27.7%, primarily due to nondeductible goodwill impairment charges and a higher effective tax rate on foreign operations. The company anticipates an increase in the global effective tax rate starting in fiscal 2025 due to OECD "Pillar Two" global minimum tax rules.
- Cybersecurity: A cybersecurity incident disclosed in July 2023 resulted in unauthorized access to systems. The investigation is complete; the incident was not material to net sales but was $0.07 dilutive to EPS for fiscal 2024 after insurance recoveries.
- Legal Proceedings: The company is facing securities class action complaints and derivative actions regarding alleged false statements. Additionally, there are 273 pending cases regarding cosmetic talcum powder and asbestos contamination.
Investor Verification Checklist
- Dr.Jart+ Strategy: Verify the execution of the strategic shift to exit the travel retail channel and the impact on future growth forecasts for the brand.
- China Market Recovery: Monitor sales trends in mainland China and Asia travel retail to assess if the "softness" in prestige beauty is stabilizing.
- Restructuring Execution: Track the progress of the Profit Recovery and Growth Plan (PRGP) to ensure cost savings targets ($350–$500 million annual benefits) are met without disrupting sales growth.
- Effective Tax Rate: Confirm the impact of the new global minimum tax rules on the effective tax rate in fiscal 2025.
- Legal Exposure: Review updates on the securities class action and talcum powder litigation to assess potential financial liabilities.